44th week of 2013 patent applcation highlights part 56 |
Patent application number | Title | Published |
20130288995 | METHODS FOR ADMINISTRATION OF CITICOLINE IN STROKE TREATMENT - The present invention provides administration methods for CDPC for treating stroke. CDPC was delivered via ECS at a concentration of 40 mmol/L-60 mmol/L. In a specific embodiment of the present invention, the concentration of CDPC administered is 50 mmol/L, CDPC is delivered at one time, the flow rate of administration is 0.2 μL/min, the volume of CDPC is 1.33 μL/mL of brain tissue, and the CDPC is administered in the caudate nucleus. The method can decrease the concentration of CDPC entering the brain and further decrease the dosage while improving efficacy. Thus, the result is improved and the probability of adverse effects due to the drug is reduced. | 2013-10-31 |
20130288996 | METHOD FOR TREATING AND PREVENTING ARTHRITIS - Compounds represented by the formula 1: | 2013-10-31 |
20130288997 | NUCLEOSIDE PHOSPHORAMIDATES - Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. | 2013-10-31 |
20130288998 | Self-Gelling Alginate Systems and Uses Thereof - Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactatates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed. | 2013-10-31 |
20130288999 | COMPOSITIONS AND METHODS FOR MODULATION OF VASCULAR STRUCTURE AND/OR FUNCTION - The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a β-1-4 conformation. | 2013-10-31 |
20130289000 | BORON-CONTAINING SMALL MOLECULES - This invention provides, among other things, novel compounds useful for treating inflammatory conditions, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. | 2013-10-31 |
20130289001 | PANTOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGIC DISORDERS - The present disclosure relates to pantothenate derivatives for the treatment of neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment of neurologic disorders. | 2013-10-31 |
20130289002 | GYRASE AND TOPOISOMERASE IV INHIBITORS - The present invention relates to a compound of formula (I) | 2013-10-31 |
20130289003 | DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES - A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy. | 2013-10-31 |
20130289004 | ANTI-STAPHYLOCOCCAL CELECOXIB DERIVATIVES - A method of treating infection by | 2013-10-31 |
20130289005 | Acne Vulgaris Treatment Regimen - A kit for treatment of acne vulgaris, said formulation of the kit effectively inhibiting or killing | 2013-10-31 |
20130289006 | COMPOSITIONS FOR TREATING HYPERPIGMENTATION AND METHODS OF USE THEREOF - Compositions are disclosed that contain an effective hyperpigmentation-treating active agent and a pharmaceutically-acceptable carrier or vehicle. Methods of using the compositions to treat hyperpigmentation are also disclosed. | 2013-10-31 |
20130289007 | METHODS FOR USING 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS - Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith. | 2013-10-31 |
20130289008 | PROGESTERONE ANTAGONISTS SUCH AS CDB-4124 IN THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, DYSMENORRHEA, BREAST CANCER, ETC. - The present invention relates to methods of administering compositions comprising a progesterone receptor antagonist for use in treating estrogen-dependent conditions. The invention is also directed to methods for treating pain associated with endometriosis. The compositions may be administered to females with endometriosis as well as to females undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. In certain embodiments, the invention provides a method for suppressing endometrial proliferation. | 2013-10-31 |
20130289009 | USE OF AT LEAST ONE COPRODUCT FROM THE VEGETABLE OIL REFINING INDUSTRY FOR OBTAINING A PURIFIED TOTAL UNSAPONIFIABLE VEGETABLE OIL PRODUCT - The present invention relates to the use of at least one vegetable oil refining industry by-product to obtain a purified total unsaponifiable of vegetable oil cleared of the impurities initially present in the said by-product, advantageously cleared of sapid and odorous compounds and/or chemical compounds resulting from the deterioration and the degradation of vegetable oils. The invention further relates to a method for obtaining a purified total unsaponifiable of vegetable oil from at least one vegetable oil refining industry by-product. The invention further relates to a purified total unsaponifiable of vegetable oil able to be obtained by this method, as well as compositions containing such an unsaponifiable. The invention further relates to such unsaponifiables or such compositions for the use thereof as a drug, medical device, dermatological agent, cosmetic agent or nutraceutical, in humans or animals. | 2013-10-31 |
20130289010 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS - 1-Phenyl-2-pyridinyl alkyl alcohol compounds are effective as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and may be used to prevent and/or treat certain diseases or conditions. | 2013-10-31 |
20130289011 | ANTIBACTERIAL DISPERSION - To provide an aqueous antibacterial dispersion which contains a metal pyrithione salt and a cationic polymer and which can maintain a stable dispersed state. An antibacterial dispersion characterized by containing at least one cationic polymer, at least one metal pyrithione salt, and at least one non-anionic surfactant. In an aqueous dispersion of the metal pyrithione salt, the non-anionic surfactant is blended instead of a conventional anionic component, whereby good dispersion stability can be maintained in a cationic polymer blend system. | 2013-10-31 |
20130289012 | 1,2,4-OXADIAZOLE AND 1,2,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 2013-10-31 |
20130289013 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS - Imidazo[1,2-a]pyridines are disclosed. Compounds of the invention are useful therapeutic agents and their inclusion in pharmaceutical formulations and use in methods of treatment are disclosed. | 2013-10-31 |
20130289014 | Combination therapy in treatment of oncological and fibrotic diseases - The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of a cell signalling and/or angiogenesis inhibitor in conjunction with an Aurora kinase inhibitor. | 2013-10-31 |
20130289015 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS - N-containing heteroaryl derivatives of formula I or II, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as JAK, particularly JAK3, kinase inhibitors. | 2013-10-31 |
20130289016 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY - Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs. | 2013-10-31 |
20130289017 | 5 (1,2,3-TRIAZOL-4-YL)-7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES - Compounds of the formula (I), in which R | 2013-10-31 |
20130289018 | New Use of Staurosporine Derivatives - This application relates to the use of staurosporines derivatives for the curative, palliative or prophylactic treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis, or mastocytosis; and to a method of treatment of warm-blooded animals in which a therapeutically effective dose of a compound of a Staurosporine Derivative is administered to a warm-blooded animal suffering from one of the diseases or conditions mentioned above. | 2013-10-31 |
20130289019 | METHODS OF TREATING BEHAVIORIAL AND/OR MENTAL DISORDERS - One embodiment of an aspect of the present invention is a method for lessening the symptoms of depression, anxiety, and post-traumatic stress disorder comprising the step of administering a therapeutically effective quantity of a cholinergic M1 receptor antagonist and a therapeutically effective quantity of one or more cholinomimetic agents to lessen the symptoms of depression, anxiety, and post-traumatic stress disorder. Typically, the cholinergic M1 receptor antagonist is selected from the group consisting of telenzepine, amytriptyline, biperiden, trihexyphenidyl, darifenacin, dicyclomine, and tiotropium. Another aspect of the present invention is directed to methods and compositions employing other therapeutic agents and combinations of therapeutic agents for emulating the theoretical pharmacological effects of the non-selective mAChR antagonist scopolamine. The invention also encompasses pharmaceutical compositions incorporating one or more therapeutic agents and a pharmaceutically acceptable carrier. | 2013-10-31 |
20130289020 | CXCR4 Receptor Antagonists - Disclosed are compounds that are antagonists of the CXCR4 receptor. | 2013-10-31 |
20130289021 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREVENTING, TREATING, OR REVERSING NEURONAL DYSFUNCTION - The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging. The compositions of the invention preferably comprise in effective amounts (a) at least one acetylcholinesterase inhibitor, (b) at least one compound with anticholinergic properties or both anticholinergic and antiglutamatergic properties, (c) optionally an anticonvulsive compound, and a pharmaceutically acceptable carrier. | 2013-10-31 |
20130289022 | TETRAMERIC ALPHA-SYNUCLEIN AND USE THEREOF - Disclosed herein are methods and related compositions for identifying compounds that stabilize natively folded tetrameric α-synuclein. These methods and compositions are useful for the treatment and diagnosis of α-synuclein-associated diseases and disorders. | 2013-10-31 |
20130289023 | METHOD FOR TREATING BRAIN TUMOR - The preset invention relates to a new method for treating brain tumor with an antipsychotic phenothiazine derivative as a brain tumor cell inhibitor or a brain tumor stem cell inhibitor. In particular, an antipsychotic phenothiazine is accessible to brain via blood-brain barrier, which should be beneficially in treatment of brain tumor. | 2013-10-31 |
20130289024 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES - The invention features compositions, methods, and kits useful for the treatment of filovirus-mediated diseases, e.g., hemorrhagic fever caused by Ebola virus, in an animal. | 2013-10-31 |
20130289025 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS - Compounds of the formula I: | 2013-10-31 |
20130289026 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins - Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: | 2013-10-31 |
20130289027 | Isoquinoline Compounds And Methods For Treating HIV - Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV). | 2013-10-31 |
20130289028 | HETEROCYCLIC FUSED ANTHRAQUINONE DERIVATIVES, MANUFACTURING METHOD AND PHARMACEUTICAL COMPOSITION USING THEREOF - A heterocyclic fused anthraquinone derivatives, which is represented by a formula (I): | 2013-10-31 |
20130289029 | Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist - The present invention belongs to the technical field of medicine, relating in particular to: a fused ring compound as represented by Formula (I) for use as a mineralocorticoid receptor antagonist, a pharmaceutically acceptable salt thereof, and an isomer thereof; a preparation method for these compounds; a pharmaceutical preparation containing these compounds; and an application of these compounds, the pharmaceutically acceptable salt thereof, or the isomers thereof in the preparation of medicants for the treatment and/or prevention of kidney injury, cardiovascular diseases such as hypertension, and/or endocrine disease. The definitions of X, Y | 2013-10-31 |
20130289030 | NOVEL PHENAZINE DERIVATIVES AND THEIR USES - The present invention is directed to novel compounds of formula I | 2013-10-31 |
20130289031 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF - The invention relates to novel products of formula (Ia) or (Ib): | 2013-10-31 |
20130289032 | ESTERS OF BENDAMUSTINE AND RELATED COMPOUNDS, AND MEDICAL USE THEREOF - The present invention relates to particular esters of bendamustine and related compounds, and medical uses thereof. | 2013-10-31 |
20130289033 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R | 2013-10-31 |
20130289034 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES - Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed. | 2013-10-31 |
20130289035 | METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) - The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity. | 2013-10-31 |
20130289036 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-B][1,2,- 4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME - The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof. | 2013-10-31 |
20130289037 | INHIBITORS OF E1 ACTIVTING ENZYMES - This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia. | 2013-10-31 |
20130289038 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS - This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. | 2013-10-31 |
20130289039 | Besylate Salts of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-oxo-6,7-- dihydro-5H-Pyrrolo[3,4-b]Pyrazine - A novel besylate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided. | 2013-10-31 |
20130289040 | MALEATE SALTS OF 6-(5-CHLORO-2-PYRIDYL)-5-[(4-METHYL-1-PIPERAZINYL)CARBONYLOXY]-7-OXO-6,7-- DIHYDRO-5H-PYRROLO[3,4-b]PYRAZINE - A novel maleate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided. | 2013-10-31 |
20130289041 | QUINOXALINE COMPOUNDS AND USES THEREOF - Disclosed herein are compounds of formula (I) and methods of inhibiting IKKβ and the NF-κB signaling and mTOR pathways. | 2013-10-31 |
20130289042 | DIMERIC IAP INHIBITORS - Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language | 2013-10-31 |
20130289043 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES - The present invention relates to compounds of formula (I) | 2013-10-31 |
20130289044 | Quinazoline Compounds as Sodium Channel Blockers - The invention relates to aryl substituted quinazolines of Formula I, and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, A, and R | 2013-10-31 |
20130289045 | AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHODS OF USING THE SAME - The present invention relates to an industrial process of preparing pharmaceutical compounds having the formula I: | 2013-10-31 |
20130289046 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS - This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. | 2013-10-31 |
20130289047 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES - Heteroarylthio compounds covalently linked to an arylpiperazine moiety for the treatment of neurological conditions. | 2013-10-31 |
20130289048 | CYCLOHEXANE DERIVATIVE COMPOUND - To find a therapeutic and/or prophylactic agent for gastrointestinal disorders and so on, the agent having excellent activity and high safety. A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents an optionally substituted phenylene group; B represents an optionally substituted 4- to 10-membered heterocyclic group, an optionally substituted C6-C10 aryl group, or an optionally substituted C3-C10 cycloalkyl group; R | 2013-10-31 |
20130289049 | ACID ADDITION SALTS OF THE 2-[2-[[(4-METHOXY-2,6-DIMETHYLPHENYL)SULFONYL]-(METHYL)AMINO]ETHOXY]-N-ME- THYL-N-[3-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL] ACETAMIDE AND THE USE THEREOF AS BRADYKININ B1 RECEPTORANTAGONISTS - The present invention relates to the new acid addition salts AB of the following free base of formula A | 2013-10-31 |
20130289050 | INHIBITORS OF BETA-SECRETASE - The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates. | 2013-10-31 |
20130289051 | ARTHROPOD PEST CONTROL COMPOSITION AND METHOD FOR CONTROLLING ARTHROPOD PESTS - Disclosed is an arthropod pest control composition having an excellent controlling effect on arthropod pests, which comprises a compound represented by formula (I) | 2013-10-31 |
20130289052 | ARTHROPOD PEST CONTROL COMPOSITION AND METHOD FOR CONTROLLING ARTHROPOD PESTS - Disclosed is an arthropod pest control composition having an excellent controlling effect on arthropod pests, which comprises a compound represented by formula (I): | 2013-10-31 |
20130289053 | DEPOT FORMULATIONS - Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity. | 2013-10-31 |
20130289054 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS - The present invention is related to novel thienopyrimidinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. | 2013-10-31 |
20130289055 | COMPRESSIBLE, HIGHLY VISCOUS POLYSACCHARIDE AND POLYOL POWDER - A powder of cold-soluble polysaccharide and polyol, which is highly viscous in water and suitable for direct compression, and a method for preparing the powder and uses thereof are described, the powder being notably intended for preparing solid forms with controlled release of an active principle. | 2013-10-31 |
20130289056 | METHODS OF ADMINISTERING AN EGFR INHIBITOR - Disclosed are methods of treating a patient having cancer with an EGFR inhibitor requiring an active step of avoiding or modifying the co-administration of such drugs with P-gp modulators. This invention also relates to a medicament for treating a patient having cancer, comprising an EGFR inhibitor as the active product ingredient, customized for avoiding co-administration with P-gp inducers and/or inhibitors by an instruction added to the medicament or the package containing said medicament. | 2013-10-31 |
20130289057 | N-ARYLAMINOMETHYLENE BENZOTHIOPHENONES FOR TREATMENT OF CARDIOVASCULAR DISEASE - The invention relates to N-arylaminomethylenebenzothiophenones of General Formula (I) for use as a drug for the treatment of cardiovascular diseases: | 2013-10-31 |
20130289058 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS - The invention relates to compounds of formula (I): | 2013-10-31 |
20130289059 | BENEFICIAL EFFECTS OF INCREASING LOCAL BLOOD FLOW - The present invention generally relates to the improvement of tissue health by increasing local blood flow. In some aspects of the invention, increased local blood flow is effected by the transdermal delivery of the nitric oxide precursor L-arginine and/or its derivatives alone, or optionally in conjunction with an adjunct such as theophylline. The transdermal delivery is effected, in certain embodiments through the means of a hostile biophysical environment, such as that created by a high ionic strength environment. Various pathological states caused by, or occurring in conjunction with, insufficient blood flow, can be treated using the systems and methods of the invention as described herein. In other embodiments, increased blood flow using the systems and methods of the invention may result in enhanced healing, for example, through greater availability of the constituents of the blood. Examples of conditions which may benefit from increased blood flow include, but are not limited to, erectile dysfunction, hair loss, female sexual dissatisfaction, sagging facial or other body tissue, peripheral vascular disease including claudication, neuropathy, skin ulcers, bone healing, wound healing, viral and bacterial infection, and skin grafting. | 2013-10-31 |
20130289060 | 6-AMIDO DERIVATIVES OF 4, 5-a EPOXYMORPHINANS FOR THE TREATMENT OF PAIN - Compounds of formula: | 2013-10-31 |
20130289061 | METHODS AND COMPOSITIONS TO PREVENT ADDICTION - Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject comprising, administering a therapeutic amount of the neurological stimulant and administering an antagonist of the kappa opioid receptor, to thereby reduce or prevent the development of aversion to the CNS stimulant in the subject. Also disclosed is a method of reducing or preventing the development of addiction to a CNS stimulant in a subject, comprising, administering the CNS stimulant and administering a mu opioid receptor antagonist to thereby reduce or prevent the development of addiction to the CNS stimulant in the subject. Also disclosed are pharmaceutical compositions comprising a central nervous system stimulant and an opioid receptor antagonist. Examples of central nervous system stimulants (such as methylphenidate) and opioid receptor antagonists (such as naltrexone) are provided. | 2013-10-31 |
20130289063 | CCR1 ANTAGONISTS AND METHODS OF USE THEREFOR - The invention provides compounds having the formula: | 2013-10-31 |
20130289064 | Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]q- uinolin-1-yl)-phenyl]-propionitrile - The invention relates to particular crystalline forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, its hydrates and solvates, its salts and hydrates and solvates of its salts, certain processes for their preparation, pharmaceutical compositions containing these crystalline forms, and their use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans. | 2013-10-31 |
20130289065 | LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON - The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments. | 2013-10-31 |
20130289066 | ANTI-ANGIOGENIC COMPOUND - A styrylquinoline derivative of structure I or IV or a benzodioxol isoquinoline of structure II or III for use in the treatment of an angiogenesis-related disease or disorder. The invention also provides a composition comprising a styrylquinoline derivative of structure I or IV or a benzodioxol isoquinoline of structure II or III for use as a medicament. | 2013-10-31 |
20130289067 | COMPOUNDS AND METHODS FOR TREATING HIV - Inhibitors of HIV-1 protease and compositions containing them are described. Use of the inhibitors and compositions containing them to treat HIV, AIDS, and AIDS-related diseases is described. | 2013-10-31 |
20130289068 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS - The present invention relates to method of enhancing the absorption of migraine medications and thereby treating migraines by co-administering to a subject in need thereof an effective amount of a ghrelin mimetic or pharmaceutically acceptable salt, hydrate or solvate thereof and at least one migraine medication selected from a serotonin 5-HT | 2013-10-31 |
20130289069 | Controlled Delivery System - The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided. | 2013-10-31 |
20130289070 | Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines - A composition for modulating generation of pro-inflammatory cytokines comprises levocabastine or a pharmaceutically acceptable salt or ester thereof. Such composition is useful for treating or controlling diseases having an inflammatory component, such as ocular diseases that are caused by inflammation or have inflammatory sequelae. | 2013-10-31 |
20130289071 | TETRAZOLYL-TETRAHYDROPYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to certain compounds according to formula (I): or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. | 2013-10-31 |
20130289072 | NOVEL INDOLE OR INDAZOLE DERIVATIVE OR SALT THEREOF - The present invention relates to provision of a novel indazole compound which is capable of inhibiting HSP90 and shows a cytostatic effect on cancer cells. The present invention also relates to provision of a drug useful for preventing and/or treating, on the basis of an HSP90 inhibitory effect, a disease in which HSP90 participates, in particular, cancer. A compound represented by the general formula (I) or a salt thereof: | 2013-10-31 |
20130289073 | CHEMICAL INHIBITORS OF CHOLESTEROL BIOSYNTHESIS AND VENOUS ANGIOGENESIS - This invention relates, e.g., to a compound, aplexone, and pharmaceutically acceptable salts and solvates, and functional variants, thereof. Methods of using the compounds and pharmaceutical compositions comprising them, e.g. to inhibit angiogenesis and to reduce cellular cholesterol levels, are also included. | 2013-10-31 |
20130289074 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS - The present invention relates to compounds of general formula I, | 2013-10-31 |
20130289075 | IAP BINDING COMPOUNDS - IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPB (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K | 2013-10-31 |
20130289076 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES - The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer. | 2013-10-31 |
20130289077 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES - The present invention relates to hydroximoyl-heterocycle derivatives of formula (I) | 2013-10-31 |
20130289078 | CONTROLLING PESTS BY COMBINING INSECTICIDES AND TRANSGENIC PLANTS BY APPLYING DIRECTLY TO LEAVES AND ROOTS - The invention relates to a method for controlling pests using a combination of insecticides and transgenic plants and consequently improving the utilization of the production potential of transgenic plants which comprises treating the plant with active compound combinations comprising an active compound from the group of the anthranilamides and at least one further insecticide. | 2013-10-31 |
20130289079 | Nicotine Lozenge Composition - The present invention relates to nicotine lozenge compositions comprising reduced levels of buffering agents from traditional nicotine lozenges and which provide optimal oral pH and prompt nicotine absorption in a smaller, more convenient dosage form. | 2013-10-31 |
20130289080 | COSMETIC COMPOSITION COMPRISING A FIXING POLYMER AND AN ANTIDANDRUFF AGENT - The invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium: one or more fixing polymer(s) (i), one or more associative polymer(s) (ii) different from the fixing polymer(s), one or more antidandruff agent(s) (iii), and to a process using this composition, and to the use thereof. | 2013-10-31 |
20130289081 | DERIVATIVES OF NICOTINIC ACID N-OXIDE, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF ENZYME 3-HYDROXYANTHRANILATE-3, 4-DIOXYGENASE - A derivative of nicotinic acid N-oxide is described having formula (I): that acts as inhibitor of enzyme 3-hydroxyanthranilate-3,4-dioxygenase (3HAO), and is thus able to reduce QUIN biosynthesis in vivo under excitotoxic or pathological conditions, said compound being at the same time also chemically stable towards auto-oxidation. | 2013-10-31 |
20130289082 | Composition and Method for Treating a Neurodegenerative Event - Disclosed is an article of manufacture featuring a support with a therapeutically effective amount of at least one fatty acid amide hydrolase (FAAH) inhibitor therein. The article has several uses and advantages including use to increase levels of at least one neurotrophin in a subject in need of such treatment. Also disclosed is a method of increasing levels of the neurotrophin in an animal by administering to a subject in need thereof at least one FAAH inhibitor. | 2013-10-31 |
20130289083 | IDO Inhibitors - Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein. | 2013-10-31 |
20130289084 | COMBINATION THERAPY - The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease. | 2013-10-31 |
20130289085 | HISTONE DEACETYLASE (HDAC) INHIBITORS TARGETING PROSTATE TUMORS AND METHODS OF MAKING AND USING THEREOF - Compounds of Formula (I), and methods of making and using thereof, are described herein; wherein AR is an aryl group, ZBG is a Zinc Binding Group, and other substituents are as defined herein. The compounds can be administered as a pharmaceutically acceptable salt, prodrug, or solvate. The compounds may be useful to treat and/or prevent hyperproliferative disorders which may include hormone sensitive and hormone refractory prostate cancers. The compounds can be formulated with a pharmaceutically acceptable carrier and, optionally one or more pharmaceutically acceptable excipients, for enteral or parenteral administration. | 2013-10-31 |
20130289086 | Aminopyrrolidinone Derivatives and Uses Thereof - The present invention provides compounds of formula I: | 2013-10-31 |
20130289087 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OVERACTIVE BLADDER - Disclosed herein are pharmaceutical compositions comprising oxybutynin or tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition. | 2013-10-31 |
20130289088 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE - The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, of enantiomers thereof, of tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2013-10-31 |
20130289089 | Pharmaceutical Compositions for Topical Delivery of Photosensitizers and Uses Thereof - The invention includes and provides compositions comprising photo | 2013-10-31 |
20130289090 | INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION - Substituted indole derivatives of formula (I) wherein the radicals have e.g. the following meaning: R | 2013-10-31 |
20130289091 | ANTISENSE ANTIBACTERIAL METHOD AND COMPOUND - A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication. The compound binds to a target mRNA with a T | 2013-10-31 |
20130289092 | COMPOUNDS AND METHODS FOR MODULATING INTERACTION BETWEEN PROTEINS AND TARGET NUCLEIC ACIDS - Provided herein are antisense compounds and methods for recruiting one or more non-cleaving protein to a target nucleic acid in a cell. In certain instances such recruitment of a non-cleaving protein alters the function or activity of the target nucleic acid. In certain such instances, the target nucleic acid a pre-mRNA and the recruitment of the non-cleaving protein results in a change in splicing of the pre-mRNA. | 2013-10-31 |
20130289093 | MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY - Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer. | 2013-10-31 |
20130289094 | Compositions and Methods for Inhibition of PCSK9 Genes - The invention relates to siRNAs targeting a PCSK9 gene, and methods of using siRNAs to inhibit expression of PC-SK9 and to treat PCSK9 related disorders, e.g., hyperlipidemia. | 2013-10-31 |
20130289095 | SYNTHETIC LETHALITY IN CANCER - There is described herein compounds, compositions and methods for inducing synthetic lethality in a cancer cell(s). | 2013-10-31 |